BACKGROUND: Neuronal damage in idiopathic parkinsonism may be in response to ubiquitous occult infection. Since peptic ulceration is prodromal, Helicobacter is a prime candidate. AIM: To consider the candidature of Helicobacter in parkinsonism with cachexia. METHODS: We explore the relationship between being underweight and inflammatory products in 124 subjects with idiopathic parkinsonism and 195 controls, and present the first case-series evidence of efficacy of Helicobacter eradication, in parkinsonism advanced to the stage of cachexia. RESULTS: Association of a low body mass index with circulating interleukin-6 was specific to parkinsonism (p = .002), unlike that with antibodies against Helicobacter vacuolating-toxin and cytotoxicity-associated gene product (p < .04). Marked reversibility in both cachexia and disability of idiopathic parkinsonism followed Helicobacter heilmannii eradication in one case, Helicobacter pylori eradication in another, follow-up being > or = 3.5 years. The latter presented with postprandial bloating, and persistent nausea: following eradication, radioisotope gastric-emptying returned towards normal, and upper abdominal symptoms regressed. Reversibility of their cachexia/disability contrasts with the outcome of anti-Helicobacter therapy where eradication repeatedly failed (one case), and in non-Helicobacter gastritis (three cases). Anti-parkinsonian medication remained constant. Intestinal absorption and barrier function were normal in all. CONCLUSION: Categorization, according to presence or absence of Helicobacter infection, was a useful therapeutic tool in late idiopathic parkinsonism.
BACKGROUND:Neuronal damage in idiopathic parkinsonism may be in response to ubiquitous occult infection. Since peptic ulceration is prodromal, Helicobacter is a prime candidate. AIM: To consider the candidature of Helicobacter in parkinsonism with cachexia. METHODS: We explore the relationship between being underweight and inflammatory products in 124 subjects with idiopathic parkinsonism and 195 controls, and present the first case-series evidence of efficacy of Helicobacter eradication, in parkinsonism advanced to the stage of cachexia. RESULTS: Association of a low body mass index with circulating interleukin-6 was specific to parkinsonism (p = .002), unlike that with antibodies against Helicobacter vacuolating-toxin and cytotoxicity-associated gene product (p < .04). Marked reversibility in both cachexia and disability of idiopathic parkinsonism followed Helicobacter heilmannii eradication in one case, Helicobacter pylori eradication in another, follow-up being > or = 3.5 years. The latter presented with postprandial bloating, and persistent nausea: following eradication, radioisotope gastric-emptying returned towards normal, and upper abdominal symptoms regressed. Reversibility of their cachexia/disability contrasts with the outcome of anti-Helicobacter therapy where eradication repeatedly failed (one case), and in non-Helicobactergastritis (three cases). Anti-parkinsonian medication remained constant. Intestinal absorption and barrier function were normal in all. CONCLUSION: Categorization, according to presence or absence of Helicobacter infection, was a useful therapeutic tool in late idiopathic parkinsonism.
Authors: André Charlett; R John Dobbs; Sylvia M Dobbs; Clive Weller; Mohammad A A Ibrahim; Tracy Dew; Roy Sherwood; Norman L Oxlade; J Malcolm Plant; James Bowthorpe; Andrew J Lawson; Alan Curry; Dale W Peterson; Ingvar T Bjarnason Journal: Gut Pathog Date: 2009-11-26 Impact factor: 4.181
Authors: Sylvia M Dobbs; R John Dobbs; Clive Weller; André Charlett; Ingvar T Bjarnason; Andrew J Lawson; Darren Letley; Lucy Harbin; Ashley B Price; Mohammad A A Ibrahim; Norman L Oxlade; James Bowthorpe; Daniel Leckstroem; Cori Smee; J Malcolm Plant; Dale W Peterson Journal: Helicobacter Date: 2010-08 Impact factor: 5.753
Authors: A Machado; A J Herrera; J L Venero; M Santiago; R M De Pablos; R F Villarán; A M Espinosa-Oliva; S Argüelles; M Sarmiento; M J Delgado-Cortés; R Mauriño; J Cano Journal: Parkinsons Dis Date: 2011-04-13
Authors: A Machado; A J Herrera; J L Venero; M Santiago; R M de Pablos; R F Villarán; A M Espinosa-Oliva; S Argüelles; M Sarmiento; M J Delgado-Cortés; R Mauriño; J Cano Journal: ISRN Neurol Date: 2011-04-17
Authors: C Blaecher; A Smet; B Flahou; F Pasmans; R Ducatelle; D Taylor; C Weller; I Bjarnason; A Charlett; A J Lawson; R J Dobbs; S M Dobbs; F Haesebrouck Journal: Aliment Pharmacol Ther Date: 2013-10-05 Impact factor: 8.171
Authors: Hasriza Hashim; Shahrul Azmin; Hamizah Razlan; Nafisah Wan Yahya; Hui Jan Tan; M Rizal Abdul Manaf; Norlinah Mohamed Ibrahim Journal: PLoS One Date: 2014-11-20 Impact factor: 3.240
Authors: R John Dobbs; André Charlett; Sylvia M Dobbs; Clive Weller; Mohammad A A Ibrahim; Owens Iguodala; Cori Smee; J Malcolm Plant; Andrew J Lawson; David Taylor; Ingvar Bjarnason Journal: Gut Pathog Date: 2012-10-19 Impact factor: 4.181